Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard
- PMID: 8495410
Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard
Erratum in
- Cancer Res 1993 Aug 15;53(16):3846
Abstract
Cyclophosphamide treatment of adult male rats leads to sustained decreases in several liver microsomal cytochrome P450 (CYP) activities, including CYP 2C11-catalyzed cyclophosphamide activation, via a process that is associated with a feminization of the overall pattern of liver enzyme expression (G. A. LeBlanc and D. J. Waxman, Cancer Res., 50:5720-5726, 1990). The present study compares the effects of cyclophosphamide and its isomeric analogue ifosphamide on the gender-dependent expression of hepatic CYP 2C11 and steroid 5 alpha-reductase in adult male rats and also examines the role of the cyclophosphamide metabolites acrolein and phosphoramide mustard in feminizing the expression of these liver enzymes. Ifosphamide (a) suppressed the male-specific CYP 2C11 mRNA and CYP 2C11-catalyzed liver microsomal testosterone 2 alpha-hydroxylation and cyclophosphamide and ifosphamide 4-hydroxylation and (b) elevated the female-dominant liver enzyme steroid 5 alpha-reductase and its mRNA 7-9 days after drug treatment, both occurring in a manner similar to that of cyclophosphamide, but requiring a 50% higher dose (180 mg/kg, single i.p. injection) to achieve these effects. This pattern of response could not be achieved by treatment of rats with acrolein or with cyclophosphamide analogues that decompose to acrolein without formation of phosphoramide mustard. In contrast, phosphoramide mustard treatment (100 mg/kg) did modulate microsomal CYP 2C11 and steroid 5 alpha-reductase activities. Treatment with a lower dose (50 mg/kg) of phosphoramide mustard or with the acrolein precursor 4-hydroperoxydechlorocyclophosphamide (200 mg/kg) alone did not affect liver enzyme expression, whereas the combination of these agents produced an overall pattern of response that was similar to that conferred by cyclophosphamide. These studies establish that ifosphamide is less potent than cyclophosphamide in modulating the pattern of cytochrome P450 and steroid 5 alpha-reductase expression and that phosphoramide mustard is responsible for the modulation of liver enzyme expression by cyclophosphamide, with acrolein potentiating the modulating activity of the mustard.
Similar articles
-
Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats.Cancer Res. 1992 Feb 1;52(3):540-7. Cancer Res. 1992. PMID: 1732040
-
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels.Drug Metab Dispos. 1994 Sep-Oct;22(5):673-9. Drug Metab Dispos. 1994. PMID: 7835216
-
Mechanisms of cyclophosphamide action on hepatic P-450 expression.Cancer Res. 1990 Sep 15;50(18):5720-6. Cancer Res. 1990. PMID: 2118418
-
Regulation of liver-specific steroid metabolizing cytochromes P450: cholesterol 7α-hydroxylase, bile acid 6β-hydroxylase, and growth hormone-responsive steroid hormone hydroxylases.J Steroid Biochem Mol Biol. 1992 Dec;43(8):1055-72. doi: 10.1016/0960-0760(92)90333-E. J Steroid Biochem Mol Biol. 1992. PMID: 22217850 Review.
-
Oxazaphosphorines: new therapeutic strategies for an old class of drugs.Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):919-38. doi: 10.1517/17425255.2010.487861. Expert Opin Drug Metab Toxicol. 2010. PMID: 20446865 Review.
Cited by
-
Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.Br J Cancer. 1998 Jun;77(11):1768-76. doi: 10.1038/bjc.1998.295. Br J Cancer. 1998. PMID: 9667645 Free PMC article.
-
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.Cancer Chemother Pharmacol. 1995;36(1):53-60. doi: 10.1007/BF00685732. Cancer Chemother Pharmacol. 1995. PMID: 7720176
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources